Potassium chloride

Generic Name: Potassium chloride

Brand Names: Bi-peglyte, Bss, Bss Ophthalmic Solution, Cardioplegic, Citrasate, Colyte, Dextrose and Electrolyte No. 75, Diphen, Eye Stream, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Glycerolyte 57, Golytely, H.E.L.P.bicel, Hemosate Ultra, Ionosol-MB, Isolyte P, Isolyte S, Isolyte S pH 7.4, Isoplate, K 45, K-tab, Klor-con, Lactated Ringers, Moviprep, Naturalyte, Normosol-R, Nulytely, Nxstage Pureflow, Olimel, Peglyte, Periolimel, Phoxillum, Physiolyte, Physiosol, Plasma-lyte, Plasma-lyte 148, Plasma-lyte 148 In 5 % Dextrose, Plasma-lyte R, Plasmalyte A, Plegisol, Plenvu, Pokonza, Prismasol, Procalamine 3, Ringers, Selectbag One, Suflave, Tis-U-sol

Drug Type: Small Molecule

Chemical Formula: ClK

CAS Number: 7447-40-7

Unique Ingredient Identifier: 660YQ98I10

Background: A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.

The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion.

Indication: For use as an electrolyte replenisher and in the treatment of hypokalemia.

Associated Conditions: Dehydration, Dry Mouth, Hypokalemia, Hypotonic Dehydration, Hypovolaemia, Isotonic Dehydration, Markedly Reduced Food Intake, Metabolic Acidosis, Hypodermoclysis, Mild Metabolic acidosis, Mild, moderate Metabolic Acidosis, Ocular edema

Associated Therapies: Acid- Base Balance, Bowel preparation therapy, Electrolyte replacement, Fluid replacement therapy, Haemofiltration, Hemodialysis Treatment, Parenteral Nutrition, Parenteral rehydration therapy, Plasma Volume Replacement, Urine alkalinization therapy, Fluid and electrolyte maintenance therapy

Clinical Trials

Balanced Solution Versus Saline in Intensive Care Study

Phase 3

Completed

Conditions: Critical Illness
Acute Kidney Injury

Interventions: Drug: Saline 0.9%
Drug: Plasma-Lyte
Other: Slow infusion speed
Other: Fast Infusion Speed

First Posted Date: 2016-08-23

Last Posted Date: 2021-04-19

Lead Sponsor: Hospital do Coracao

Target Recruit Count: 11075

Registration Number: NCT02875873

Locations: 🇧🇷
Alexandre Biasi Cavalcanti, São Paulo, SP, Brazil

Decision Support for Intraoperative Low Blood Pressure

Not Applicable

Completed

Conditions: Hypotension

Interventions: Procedure: Attending real-time decision support
Procedure: In-room real-time decision support
Procedure: Attending feedback emails
Procedure: In-room provider feedback emails
Device: Anesthesia Information Management System (AIMS)
Device: Perioperative Data Warehouse (PDW)
Procedure: General anesthesia
Device: Pager system
Procedure: Central neuraxial anesthesia
Procedure: Non-cardiac surgery
Drug: Propofol
Drug: Sevoflurane
Drug: Desflurane
Drug: Isoflurane
Drug: Ephedrine
Drug: Phenylephrine
Drug: Norepinephrine
Drug: Epinephrine
Drug: Dobutamine
Drug: Sodium Chloride 0.9%
Drug: Dopamine
Drug: Isoproterenol
Drug: Milrinone
Drug: Atropine
Drug: Glycopyrrolate
Drug: Vasopressin
Drug: Terlipressin
Drug: Ringer's lactate
Drug: Hydroxyethyl starch solutions
Drug: Fresh Frozen Plasma
Drug: Packed Red Blood Cells
Drug: Albumin solutions
Drug: Plasma-Lyte
Drug: Lidocaine
Drug: Bupivacaine
Drug: Levobupivacaine
Drug: Ropivacaine
Drug: Mepivacaine
Drug: Tetracaine
Drug: Prilocaine
Drug: Procaine
Drug: Chloroprocaine
Drug: Benzocaine
Drug: Articaine

First Posted Date: 2016-04-04

Last Posted Date: 2019-05-16

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 22435

Registration Number: NCT02726620

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis

Phase 4

Conditions: Nephrotoxicity

Interventions: Drug: 0,9% saline
Drug: Plasma-lyte

First Posted Date: 2015-08-19

Last Posted Date: 2015-08-19

Lead Sponsor: Regional Hospital Holstebro

Target Recruit Count: 40

Registration Number: NCT02528448

Locations: 🇩🇰
Department of Medical Research, Regional Hospital Holstebro, Holstebro, Denmark

Beneficial Bacteria Treatment for Autism

Phase 1

Completed

Conditions: Gastrointestinal Problems
Autism Spectrum Disorders

Interventions: Drug: oral Vancomycin
Drug: MoviPrep
Drug: Prilosec
Biological: human fecal material; processed, frozen administered orally
Biological: human fecal material; processed, frozen; administered orally and rectally

First Posted Date: 2015-07-22

Last Posted Date: 2019-12-18

Lead Sponsor: Arizona State University

Target Recruit Count: 18

Registration Number: NCT02504554

Prevention of Severe Postpartum Hypertension

Phase 2

Withdrawn

Conditions: Hypertension

Interventions: Drug: Placebo #1
Drug: Furosemide
Drug: Placebo #2
Drug: Potassium chloride

First Posted Date: 2015-05-21

Last Posted Date: 2023-05-11

Lead Sponsor: Indiana University

Registration Number: NCT02450773

Locations: 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF

Phase 2

Completed

Conditions: Heart Failure
Diastolic Heart Failure

Interventions: Drug: KNO3
Drug: KCl

First Posted Date: 2014-10-03

Last Posted Date: 2017-10-03

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 12

Registration Number: NCT02256345

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: NER1006
Drug: Moviprep

First Posted Date: 2013-04-18

Last Posted Date: 2013-04-18

Lead Sponsor: Norgine

Target Recruit Count: 161

Registration Number: NCT01834742

Locations: 🇷🇴
Pierrel Research HP-RO-SRL, Timisoara, Romania

Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter

Phase 4

Completed

Conditions: Atrial Fibrillation
Atrial Flutter

Interventions: Drug: Potassium chloride
Drug: Glucose 50 MG/ML

First Posted Date: 2013-03-26

Last Posted Date: 2018-07-31

Lead Sponsor: Diakonhjemmet Hospital

Target Recruit Count: 143

Registration Number: NCT01818583

Locations: 🇳🇴
Diakonhjemmet Hospital, Oslo, Norway

Efficacy of Steroid Supplementation After TMJ Rinsing for Pain Management

Phase 2

Completed

Conditions: Pain

Interventions: Drug: Triamcinolone hexacetonide
Drug: Lactated Ringers

First Posted Date: 2013-01-18

Last Posted Date: 2020-10-08

Lead Sponsor: University of Florida

Target Recruit Count: 24

Registration Number: NCT01770912

Locations: 🇺🇸
University of Florida College of Dentistry, Gainesville, Florida, United States

Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation

Phase 3

Completed

Conditions: Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.

Interventions: Drug: MOVIPREP

First Posted Date: 2012-11-26

Last Posted Date: 2014-05-15

Lead Sponsor: Takeda

Target Recruit Count: 140

Registration Number: NCT01732692

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy